Form 4: Applied Therapeutics Director Sells 43,000 Shares

A director at Applied Therapeutics, Stacy J. Kanter, sold 43,000 shares of common stock at an average price of $0.112 per share.

Summary

• Stacy J. Kanter, a Director of Applied Therapeutics, Inc. (APLT), reported a sale of common stock.
• The transaction involved the disposition of 43,000 shares of common stock.
• The shares were sold on December 16, 2025, at a weighted average price of $0.112 per share.
• The sale was executed in multiple transactions with prices ranging from $0.1111 to $0.1130.
• Following this transaction, Stacy J. Kanter beneficially owns 65,000 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to a director selling a significant number of shares, which can be perceived as a lack of confidence, despite the transaction being under a 10b5-1 plan. The low share price of the sale also contributes to this sentiment.

Negatives

• A director selling a significant number of shares (43,000) could be perceived negatively by investors, potentially signaling a lack of confidence in the company's near-term prospects.
• The sale occurred at a relatively low price point of $0.112 per share.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider sales, even those pre-arranged under a 10b5-1 plan, are closely watched by the market as they can sometimes indicate management's perception of future company performance or valuation. In the biotechnology or pharmaceutical industry, where Applied Therapeutics operates, such transactions can influence investor sentiment, especially given the inherent risks and volatility.

Related Party Transactions

• The transaction involves a director of the company, Stacy J. Kanter, selling shares of the issuer, which is considered an insider transaction.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal of reduced confidence, potentially leading to negative pressure on the stock price.
• Potential impact on investor sentiment regarding the company's valuation and future prospects.

Key Dates

Recommendation

While a director's sale, even under a 10b5-1 plan, can be a negative signal, it's a single transaction and doesn't necessarily indicate a fundamental shift in the company's long-term outlook. Given the low price of the sale, it suggests the director is taking profits or rebalancing their portfolio rather than a strong bearish bet. Investors should hold and monitor future developments and broader company performance rather than making a decision solely based on this insider sale.

Keywords

Applied Therapeutics, APLT, Insider Sale, Form 4, Director Transaction, Stacy J. Kanter, Stock Sale, 10b5-1 Plan